Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 754-764 , December 2009

Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: A review of current guidelines

Received 2 June 2009 ,Revised 18 August 2009 ,Accepted 19 August 2009.

References 

  1. Bergqvist D, Caprini JA, Dotsenko O, Kakkar AK, Mishra RG, Wakefield TW. Venous thromboembolism and cancer. Curr Probl Surg. 2007;44(3):157–216
  2. de Lorenzo F, Dotsenko O, Scully MF, Tymoshchuk M. The role of anticoagulation in cancer patients: facts and figures. Anticancer Agents Med Chem. 2006;6(6):579–587
  3. Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb Res. 2007;120(Suppl. 2):S137–S140
  4. Carrier M, Lee AY. Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol. 2009;6(2):74–84
  5. Lee AY. Treatment of venous thromboembolism in cancer patients. Best Pract Res Clin Haematol. 2009;22(1):93–101
  6. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th ed.). Chest. 2008;133(6 Suppl.):381S–453S
  7. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th ed.). Chest. 2008;133(6 Suppl.):454S–545S
  8. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–5505
  9. Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist. 2007;12(11):1361–1370
  10. National Cancer Comprehensive Network Clinical Practise Guidelines in Oncology. Venous Thromboembolic Disease.V.1.2009. <http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf>.
  11. Mandala M, Falanga A, Piccioli A, Prandoni P, Pogliani EM, Labianca R, et al. Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol. 2006;59(3):194–204
  12. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005;16(5):696–701
  13. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17):1169–1173
  14. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91(1):92–95
  15. Lee AY. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematol Am Soc Hematol Educ Program. 2006;438–443
  16. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Int Med. 2000;160(6):809–815
  17. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722
  18. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346
  19. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634
  20. Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost. 1999;25(2):239–243
  21. Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005;94(4):867–871
  22. Martino MA, Borges E, Williamson E, Siegfried S, Cantor AB, Lancaster J, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol. 2006;107(3):666–671
  23. Trujillo-Santos J, Ruiz-Gamietea A, Luque JM, Samperiz AL, Garcia-Bragado F, Todoli JA, et al. Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res. 2009;123(Suppl. 2):S10–S15
  24. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401–410
  25. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285–291
  26. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850
  27. Martino MA, Williamson E, Siegfried S, Cardosi RJ, Cantor AB, Hoffman MS, et al. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol. 2005;98(2):289–293
  28. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89–95
  29. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Int Med. 2004;164(9):963–968
  30. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529–535
  31. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Int Med. 2000;160(6):769–774
  32. Khorana AA, Rao MV. Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res. 2007;120(Suppl. 2):S41–S50
  33. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102(6):V215–V224
  34. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62(2):126–136
  35. Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis. Thromb Haemost. 1993;70(3):540–542
  36. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87(4):575–579
  37. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318(18):1162–1173
  38. ENOXACAN Study Group . Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84(8):1099–1103
  39. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14(4):341–346
  40. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8(4):381–388
  41. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–394
  42. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AG, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007;119(2):145–155
  43. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132(3):936–945
  44. Kalka C, Spirk D, Siebenrock KA, Metzger U, Tuor P, Sterzing D, et al. Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Electronic Assessment of VTE Prophylaxis in High-Risk Surgical Patients at Discharge from Swiss Hospitals (ESSENTIAL). Thromb Haemost. 2009;102(1):56–61
  45. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318(7):404–407
  46. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–1662
  47. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479–484
  48. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14(10):2731–2737
  49. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343(8902):886–889
  50. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer. 2008;112(7):1522–1528
  51. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost. 2007;97(6):1031–1036
  52. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296(21):2558–2560
  53. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–1239
  54. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–2285
  55. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost. 2008;99(1):38–43
  56. Cunningham MS, White B, Hollywood D, O’Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence. Br J Cancer. 2006;94(2):189–194
  57. Chan A, Iannucci A, Dager WE. Systemic anticoagulant prophylaxis for central catheter-associated venous thrombosis in cancer patients. Ann Pharmacother. 2007;41(4):635–641
  58. Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost. 2007;5(12):2552–2554
  59. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60–68
  60. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484–490
  61. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793–800
  62. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874–879
  63. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325–329
  64. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther. 2007;29(11):2395–2405
  65. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988;208(2):227–240
  66. The European Fraxiparin Study (EFS) Group . Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg. 1988;75(11):1058–1063
  67. Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP, H.B.P.M. Research Group . Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg. 1991;78(4):412–416
  68. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, et al. The Thromboprophylaxis Collaborative Group Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet. 1993;341(8840):259–265
  69. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg. 1995;82(4):496–501
  70. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83(1):14–19
  71. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005;92(10):1212–1220
  72. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4(11):2384–2390
  73. Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg. 1998;164(9):657–663
  74. Rasmussen MS. Prolonged thromboprophylaxis with low molecular weight heparin after major abdominal surgery. Curr Opin Pulm Med. 2007;13(5):389–392
  75. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–980
  76. Ingber S, Geerts WH. Vena caval filters: current knowledge, uncertainties and practical approaches. Curr Opin Hematol. 2009;16(5):402–406
  77. Young T, Tang H, Aukes J, Hughes R. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev. 2007;(4):[CD006212]
  78. Getzen TM, Rectenwald JE. Inferior vena cava filters in the cancer patient: current use and indications. J Natl Compr Canc Netw. 2006;4(9):881–888
  79. Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(6):577–584
  80. Hull RD, Pineo GF. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?. Semin Thromb Hemost. 2004;30(Suppl. 1):11–23
  81. Holzheimer RG. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur J Med Res. 2004;9(4):225–239
  82. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Int Med. 1999;130(10):800–809
  83. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996;100(3):269–277
  84. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Int Med. 2000;160(2):181–188
  85. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;101(4):762–769
  86. Akl E, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2008;(1):[CD006649]
  87. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337(10):657–662
  88. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der MJ, et al Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334(11):682–687
  89. Hyers TM, Spyropoulos AC. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. J Thromb Thrombolysis. 2007;24(3):225–232
  90. Ageno W, Grimwood R, Limbiati S, Dentali F, Steidl L, Wells PS. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica. 2005;90(2):220–224
  91. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488
  92. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18(17):3078–3083
  93. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110(5):1149–1161
  94. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007;120(1):72–82
  95. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153
  96. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062–1072
  97. Romera A, Cairols MA, Vila-Coll R, Marti X, Colome E, Bonell A, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2009;37(3):349–356
  98. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Int Med. 2002;162(15):1729–1735
  99. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389–396
  100. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. Chest. 2006;130(6):1808–1816
  101. Louzada ML, Majeed H, Wells PS. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2009;123(6):837–844
  102. Carrier M, Le GG, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7(5):760–765
  103. The PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112(3): 416–22.
  104. Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Int Med. 2007;146(3):204–210
  105. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53(1):93–105
  106. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost. 2007;33(7):688–694
  107. Niers TM, Klerk CP, DiNisio M, Van Noorden CJ, Buller HR, Reitsma PH, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol. 2007;61(3):195–207
  108. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 1999;82(2):947–952
  109. Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR. The effects of unfractionated heparin on survival in patients with malignancy – a systematic review. Thromb Haemost. 1999;82(6):1600–1604
  110. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22(10):1944–1948
  111. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130–2135
  112. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123–2129
  113. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006;81(6):758–767
  114. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2(8):1266–1271
  115. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev. 2007;33(4):358–368
  116. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev. 2007;(3):[CD006652]
  117. Akl EA, Kamath G, Kim SY, Yosuico V, Barba M, Terrenato I, et al. Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev. 2007;(2):[CD006466]
  118. Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Int Med. 2005;165(7):733–738
  119. Simonneau G, Laporte S, Mismetti P, Derlon A, Samii K, Samama CM, et al. A randomized study comparing the efficacy and safety of nadroparin 2850IU (0.3mL) vs. enoxaparin 4000IU (40mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006;4(8):1693–1700
  120. Mousa SA. Are low molecular weight heparins the same?. Methods Mol Med. 2004;93:49–59
  121. Mousa SA. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002;20(3):199–216
  122. Merli GJ, Vanscoy GJ, Rihn TL, Groce JB, McCormick W. Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins. J Thromb Thrombolysis. 2001;11(3):247–259
  123. Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost. 2008;34(1):74–85
  124. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl.):188S–203S
  125. Rondina MT, Pendleton RC, Wheeler M, Rodgers GM. The treatment of venous thromboembolism in special populations. Thromb Res. 2007;119(4):391–402
  126. Davidson BL, Buller HR, Decousus H, Gallus A, Gent M, Piovella F, et al. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007;5(6):1191–1194
  127. Michota F, Merli G. Anticoagulation in special patient populations: are special dosing considerations required?. Cleve Clin J Med. 2005;72(Suppl. 1):S37–S42
  128. Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost. 2007;5(5):937–941
  129. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57(8):1487–1495
  130. Launay-Vacher V, Izzedine H, Rey JB, Rixe O, Chapalain S, Nourdine S, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004;10(5):CR209–CR212
  131. Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med. 2007;13(5):409–413
  132. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Int Med. 2006;144(9):673–684
  133. Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf. 2005;28(4):333–349
  134. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003;43(6):586–590
  135. Mahe I, Gouin-Thibault I, Drouet L, Simoneau G, Di CH, Siguret V, et al. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging. 2007;24(1):63–71
  136. Mahe I, Aghassarian M, Drouet L, Dit-Sollier CB, Lacut K, Heilmann JJ, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost. 2007;97(4):581–586
  137. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, d’Azemar P, Necciari J, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost. 1998;79(6):1162–1165
  138. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf. 2002;25(10):725–733
  139. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175anti-XaIU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84(5):800–804
  140. Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care. 2008;12(2):R32
  141. Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, et al. Dalteparin thromboprophylaxis for critically ill medical–surgical patients with renal insufficiency. J Crit Care. 2005;20(4):357–363

PII: S0305-7372(09)00123-6

doi: 10.1016/j.ctrv.2009.08.009

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 754-764 , December 2009

Article Tools